EL.En. S.p.A. (ELN) Earnings Call Transcript & Summary

November 17, 2025

Borsa Italiana IT Health Care Health Care Equipment and Supplies earnings 54 min

Earnings Call Speaker Segments

Moderator

operator
#1

Good afternoon, or good morning depending on where you're joining from, and thank you for being here for El.En.'s conference call on the 3Q 2025 financial results. This session is being recorded, and you'll have a chance to ask questions toward the end. Joining me are Andrea Cangioli, El.En.'s CEO, and Enrico Romagnoli, El.En.'s Chief Financial Officer and Investor Relations Manager. Before we start, I'd like to point out that during this conference call, management will make remarks about future expectations, plans, prospects, and forward-looking statements. Some of the statements made today — including any that address the company's beliefs, plans, objectives, estimates, or expectations concerning possible future results or events — constitute forward-looking statements. Such statements carry known or unknown risks, among them general economic and business conditions in the industry and the assumptions about the environment in which we operate. Should our assumptions prove inaccurate, these statements may be affected. As a result, no forward-looking statement can be guaranteed, and actual future results, performance, or achievements could differ materially from what such forward-looking statements express or imply. The company assumes no obligation to update the contents or the forward-looking statements to reflect events or circumstances arising after today's date. Once the presentation wraps up, if you'd like to ask a question, please book it in the chat of Bianca Fersini Mastelloni or raise your virtual hand.

Moderator

operator
#2

We'll take you in the sequence your requests came in. Right now, I'd like to hand things over to Andrea Cangioli. Andrea, the floor is yours.

Andrea Cangioli

executive
#3

Thanks so much, Bianca, for that introduction and for having us on, and thank — thank you all for joining this call after we released our financial reports as of September 30th, 2025. Enrico Romagnoli is here with me on this call, and I appreciate him handling the specifics of our financial reporting, which he'll be sharing with you very shortly. Our third quarter was really strong, particularly on the profitability side, confirming the trend of this 2025: a brilliant performance in the medical sector and a softer one in the industrial business. The reported numbers show that on the nine months revenues rose 4.6% in medical and just shy of 2% in industrial, and that consolidated EBIT fell 3.2% on the nine months, but rose 3.8% in the quarter, marking the EBIT recovery that hints at and supports our guidance for this year-end. If we look a little deeper inside these numbers, we have grounds to be extremely pleased with the performance in the medical sector, also on the revenue line. In fact, this 2025 — in this 2025, we're facing the inorganic effect of the exit of consolidation from March 1st of the Japanese subsidiary With us.

Andrea Cangioli

executive
#4

After accounting for that impact, medical growth for the nine months would have come in at 7.1%. On top of that, we are dealing with the departure of a long-standing and very substantial customer, Cynosure, since our OEM agreement to supply high-power alexandrite laser systems for hair removal is only formally in effect after Cynosure merged with a South Korean company, Lutronic, which now supplies — and will continue supplying — that technology to Cynosure for its distribution network. If you strip out the negative impact of that situation and combine it with removing the With us effect, sales growth for the nine months would have been above 10%. That covers the revenue side. Another piece of good news this period is that the revenue gain comes alongside higher revenues in sales segments and products that carry better margins, with a favorable overall impact on consolidated gross margins and profitability as a whole. Systems sales growth came mostly from systems for anti-aging treatments, where the innovative content of both the technology and the application delivers a higher margin for us than the main, slowly declining revenue stream from hair removal devices. I'm referring first and foremost to the Onda PRO, a reworking of our flagship body contouring device Onda built on microwaves technology — a reworking that broadened the device's intended use to anti-aging facial treatments.

Andrea Cangioli

executive
#5

With that in mind, Onda PRO is enjoying a second youth compared with the original Onda launch, and it has been amazingly well received even in the most advanced markets for aesthetic innovation — namely Far East markets such as Korea, which are extremely developed and sophisticated when it comes to choosing the most innovative and effective devices. Since our group does not depend on peak performance from any single product device, Onda PRO was not the only thing pushing revenues toward anti-aging demand. Let me give you just a couple more examples of other successful products and the procedures tied to them. Nano- and picosecond devices such as the Discovery Pico by Quanta System and the Torro by DEKA lead innovation in the pigmented lesions skin toning area, which has traditionally been prominent for treating — for treating aging facial skin in the Far East. The CO2 micro-ablative procedure CoolPeel, performed by DEKA's Tetra PRO, is now the golden standard for facial rejuvenation and is seeing growing success worldwide, starting with the US market. The surgical business also made another significant contribution to performance, especially in urological applications, which are the treatment of stones — Sí, bueno, me ha dicho... o sea, si esto se aprueba la semana que viene...

Andrea Cangioli

executive
#6

Álvaro, Álvaro,

Enrico Romagnoli

executive
#7

Pardon me. ...you’ve got a whole lot of things on the table for next week, if this...

Andrea Cangioli

executive
#8

We need to take out... I'm not sure, there's a message someone forwarded to me... Please, Álvaro, we can hear you. Álvaro. Ecco, thank you. The surgical business also made another significant contribution to performance, particularly in the urological application — that is, treatment of stones and BPH, benign hyperplasia of the prostate — a business that within the group is mainly pursued by the market leader, Quanta System, but also by JenaSurgical, the brand managed by our German sub, Asclepion. Revenue for laser systems in urology rose approximately 7.5% over the nine months. The side business of consumables, sterile optical fiber, also grew smoothly in line with the increasing installed base, and it now represents more than half of our post-sales revenues in the medical business, which means roughly €10 million per quarter, or 10% of the overall revenues of our medical business. Moreover, this revenue stream carries gross margins that sit in the upper segment of our product margin mix, and since operation expense in terms of sales and marketing and labor is less intensive than for system sales, the accretive impact on EBIT and EBIT margins is also significant, as testified by the profitability of Quanta System, which is the main actor in this business for us.

Andrea Cangioli

executive
#9

On the expense side for this business, capex is underway and more is coming at Quanta System, since Quanta System has begun building a new, bigger, semi-robotized clean room at its Samarate facility. That room will be devoted to making sterile optical fibers, boosting production capacity for this medical device. For the medical division's EBIT margin — this is an unaudited figure I'm giving you — it is improving in 2024 to 2025 on 2024, at roughly 16.9% for the nine months and around 19% in the third quarter. We could not deliver comparable results in our industrial business. The sole activity with margins like the medical business is the identification marking activity led by Lasit, which keeps performing well in both revenues and profitability. The remaining businesses in our industrial world did not perform according to expectation — the expectation in our yearly planning — missing revenue targets and also lagging on profit generation. The most dimensionally significant business is cutting, which despite expansive expectation and decent order bookings has been slowing in both revenues and profits in each quarter this year. Because order bookings arrived quite late in the year and delivery lead times for our sophisticated and often custom-designed systems cannot easily be compressed, as of September 30 we incurred a major sales cut-off — meaning we were unable to recognize revenues for several systems physically delivered to customers but which had not cleared the final testing procedure within the end of the month.

Andrea Cangioli

executive
#10

To give you a sense of this adjustment—which, to some degree, always occurs physiologically at the close of every quarter—we are discussing almost €8 million at the end of September compared with less than €1 million at the end of June, a €7 million figure representing 22% of quarterly business revenue and 7% of year-to-date revenues as of September. I am not saying that absent this adjustment everything would have been fine in this business segment, since the market is highly competitive and a major effort is required from us to hold our competitive position and secure our sales, but naturally, it would have appeared different from several perspectives. In fact, we keep investing in what we consider strategically significant for Cutlite's market positioning in the sheet metal laser business, which can be summed up in three points that generate capex or profit and loss outflows in 2025: the acquisition of a plant to expand Cutlite Penta's versatile production capacity, which we closed in the first quarter of 2025; the P&L expenses tied to launching the European sales subsidiaries so as to get closer to customers in Spain, Germany, and Poland; the profit and loss costs tied to managing Nexan, the company devoted to automation systems complementary to our laser cutting system, an addition to the product range that is highly strategic for the product offering, but that for the time being is far from being EBIT accretive, though it is improving its EBIT result in the third quarter.

Andrea Cangioli

executive
#11

Now regarding the remaining smaller industrial businesses: the laser marking systems for special applications and large surfaces that Ot-Las supplies, as well as those from El.En.'s industrial division — frequently delivered together with mid-power CO2 laser sources — in these areas performance remained soft. We are hunting for new application niches to claw back ground in a year battered by the downturn among fashion-industry customers and also by reduced expectations in the electric-vehicle motor segment. Cash generation was exceptional this quarter, helped by the one-time inflow from selling the majority stake in Penta Laser Zhejiang, which, already accounting for potential future price adjustments, was worth about €26.4 million to the net financial position. As I said earlier — and by earlier I mean in conference calls we've held previously — if we had closed that deal three months sooner, the exchange rate against the Chinese yuan would have been far better, since it deteriorated rapidly by roughly 10% around and following Liberation Day. Operating cash flows came to approximately €20 million, adding to the €47 million rise in the net financial position for the quarter.

Andrea Cangioli

executive
#12

With this profile in mind, I should note that during the quarter there was a modest reduction in overall net working capital, and capital expenditure came to about €3 million, which was offset in its effect on the net financial position by the release of €3 million of long-term cash investment that cannot appear in the net financial position. Incidentally, the balance of those investments, which are not counted within the net financial position because they are a long-term asset, stood at approximately €11 million as of the close of the third quarter of 2025. I'll hand things over to Enrico, and after his section I'll return with some broader comments.

Enrico Romagnoli

executive
#13

Thanks, Andrea. Morning, everyone. As always, I'll walk through the financials that we published last week. For the year-end and for the half-yearly report, the quarterly report was drafted following IFRS accounting standards, leaving out the line-by-line consolidation of the Chinese activities in both 2025 and 2024, because of the negotiation to sell that division under IFRS 5. The majority stake in the Chinese companies was sold on July 15; since July 2025, Penta Laser Zhejiang has been consolidated using the equity method for the remaining 19.3% stake. During the first nine months of 2025, the group posted consolidated revenue of €422 million, an increase of 3.9% versus the €406 million, with the medical sector rising more than 4.6% while the industrial sector was up 1.9%. Gross margin came in at €188.3 million, 6.5% higher than the €177 million of September 2024, equal to 44.6% of revenue, which improved profitability by 1% versus last year. It's worth noting that in 2024 the group booked proceeds from insurance and government reimbursement tied to damages from the flood of November 2023 totaling €1.9 million, or 0.5% of revenue.

Enrico Romagnoli

executive
#14

In 2025, Asclepion recorded €1.3 million in R&D grants, which equals 0.3 percentage point of revenue. If you strip out both of those nonrecurring items, the gross margin's effect on sales would have shown an improvement of more than 1% in 2025, driven by a better sales mix. Operating expenses rose both in absolute value and as a share of sales, chiefly in G&A, R&D, and IT cost, plus sales and marketing activities. Staff cost went up because of higher headcounts and higher salaries. EBITDA was positive at €65.6 million. That result matches last year, even though the EBITDA margin in 2025 dipped slightly from 16.2% to 15.6%. Depreciation, amortization, and provision came to €10.6 million in 2025 versus €9 million in 2024. The increase was mainly due to the reversal in 2024 of the provision for risk and charges of €1.6 million, stemming from certain legal disputes that were resolved more favorably than expected. Net of that amount, the overall cost aggregate is in line with the prior year. EBIT for the first nine months was €55 million, compared with €56.9 million for the first nine months of 2024. Margin on revenue was 13%, down from 14%, a decrease over last year of 3.3%, which halves the gap recorded at June.

Enrico Romagnoli

executive
#15

Financial management posted a loss of €1.8 million. Over the first nine months, liquidity brought in interest income of €2.8 million, whereas interest expenses on debt came to €1.3 million. Exchange rate differences show a sharply negative balance of €2.4 million, and on top of that there is a one-time exchange rate loss already booked in Q1 amounting to €908,000, stemming from the release of the currency conversion reserve tied to the sale of the majority of With us. The associated company contribution is negative at €1 million, mainly With us at -€0.5 million and Penta Laser Zhejiang at -€0.6 million. Within other income, last year included a one-time gain of €5 million from writing off a liability linked to the earn-out payable to former minority Chinese shareholders should Penta Laser Zhejiang complete an IPO. Ultimately, income before taxes came out positive at €52.2 million, below the €61.2 million seen at the end of September 2024. In the third quarter, as Andrea already noted, the group performed strongly, recording growth in revenue and, most importantly, in operating profit, up 3.8% versus Q3 2024, a sharp rebound from June, when the EBIT shortfall relative to the first six months of 2024 stood at 7%.

Enrico Romagnoli

executive
#16

During Q3, the segments that turned in stronger results versus a year earlier were primarily aesthetics within medical and marking within industrial. Turning to cash flow, the group's net financial position as of September 2025 stood at a positive €137 million — up €47.4 million in the third quarter compared with €90 million at the close of June 2025. Over the nine months, the gain came to €26.8 million, driven by cash generated from ongoing operations plus proceeds from disposing of the majority stake in Penta Laser Zhejiang, which brought in a net €26.4 million. The principal outflows during that period were dividends of €19 million paid in Q2, capex of €13 million across the nine months, and a €20 million rise in net working capital. On top of that, the group placed liquidity into insurance policies — a mid-to-long-term investment carried under noncurrent assets — giving us a further €10.7 million of liquidity as of September 30. As for revenue by business, within medical, system sales posted robust gains across every major segment. Aesthetics rose 4%, with the highly favorable momentum in anti-aging and body contouring applications continuing. Within surgical applications, up 8%, urology, ENT, and gynecology systems kept delivering meaningful sales growth.

Enrico Romagnoli

executive
#17

Physiotherapy also did well, up 5%, which we owe to substantial innovation across the product lineup, more effective reach into international markets, and the restart of sales in Italy. Consumables and after-sales service stayed very solid, powered by optical fiber sales for surgical use — over 50% of segment sales — which held service revenue growth at 4% even with the loss of service contract revenue from the Japanese company With us, whose majority stake was sold in February 2025. On the industrial side, the cutting segment, which no longer includes the Chinese companies, kept growing at 2%, helped by an excellent sales performance from the Brazilian subsidiaries, adding €4 million of revenue in the first nine months. Lasit also turned in a good performance in the marking segment, with growth at its subsidiaries. In Q3, we saw a significant rebound in sales within the large surface marking application segment, where Ot-Las operates. In laser sources, the deceleration was clearer and stemmed mainly from lower revenues from system integrators serving fashion applications and electric motor windings. Industrial service sales were back to an increase of 6%, in line with expectations, driven by the steady expansion of the installed base.

Enrico Romagnoli

executive
#18

Looking at geography, Italy gave us the best news, posting an exceptional 27% rise in medical. On the industrial side, Italian revenue bounced back as well during the quarter, gaining 6% across the nine months, helped by greater confidence among manufacturing operators, which was backed by investment-support tax measures coming back. Results in the European market were highly pleasing, especially in German medical and professional aesthetics beauty, and in industrial too, driven by the steady consolidation of the sales subsidiaries' work, Lasit in particular. The negative figure showing up in rest-of-world sales stems from different causes by segment. On medical, Andrea has already covered the inorganic transaction that hit the sector. It is nonetheless a solid result, since it came in net of the February exit of With us and the loss of supplies to Cynosure stemming from the M&A that pulled it closer to Lutronic. So, excluding that departure, revenue climbed considerably. Industrial tells a wholly different story: there, our order intake in the American market — the biggest part of rest of world — took a hit in the year's first month from how the market pictured the possible acquisition by a Chinese entity.

Enrico Romagnoli

executive
#19

Andrea, go ahead please regarding the guidance.

Andrea Cangioli

executive
#20

To wrap up my prepared remarks, I'd like to address three additional subjects: the part played by the industrial division—particularly the cutting division—inside the group, how we deploy our cash, and last, the 2025 guidance. Since the industrial division's performance, and notably that of the cutting division, is weaker than the rest of the group's, I want to walk you through the group's strategy, both short-term and mid-term, regarding this business area. We take great pride in what our cutting business unit has achieved in results and in scale, yet we also recognize that its business—especially once fiber laser sources technology pushed CO2 laser sources out of cutting—no longer aligns fully with the group's other businesses. There is no market correlation, and the technological correlation is quite limited too. So we are convinced that the Cutlite Penta organization, its people and its business, would gain from strategically cooperating with organizations that fit more closely with Cutlite's business. Along this path, we pursued a transaction that would have put Cutlite inside a larger organization developing a dedicated growth strategy for Cutlite. I'm referring to potential sales to the Chinese entity.

Andrea Cangioli

executive
#21

Faced with a material risk under the new organization—namely that Cutlite's US business, one of its most promising operations, was in danger of being entirely compromised—we made the decision that, in order to protect the organization itself, we would no longer sell Cutlite. As for the short-term approach, now that Cutlite remains inside our consolidation perimeter, the plan is to manage its potential and keep investing in whatever we believe Cutlite needs in order to flourish. Over the longer term, the strategy is to pick back up and carry forward the effort to design a strategic partnership for Cutlite—one that would strengthen its distinctive traits, capabilities, and potential, thereby giving Cutlite's organization the best opportunity to keep flourishing, or rather, to improve its opportunities and chances of flourishing in its market, which is quite competitive. What our reporting makes evident is how much investment is involved in supporting Cutlite's strategy. As for what more we can tell you about the bigger picture, there isn't much at all at the moment, but we will update you as soon as we have something meaningful to report. Regarding the businesses of Lasit, Ot-Las, and the industrial division of the mother company, El.En., we intend to continue pursuing those businesses within the group.

Andrea Cangioli

executive
#22

So the fairly substantial cash balance we're sitting on right now goes past what our businesses need for normal operations, and it also takes into account possible expansion investments, such as the sterile optical fiber manufacturing plant I brought up. For us, capital expenditure and the operating requirements of our businesses always come first, since we think attractive growth rates are achievable through further gains in how our own business units perform. To lift our growth rate, particularly on the profit side, we're looking into a group of small M&A opportunities that might add to the development of the units involved, above all in the medical sector and in the industrial sector too, as we said earlier. Along these lines, we might close one or more small deals before long. Deals of a more complex kind, the sort that could be labeled transformational, are currently getting closer consideration, although there's nothing to report on that front at the moment. Regarding any one-time cash distribution to shareholders, in whatever form, the Board of Directors hasn't reached a decision yet. So I'm not in a position to offer any comment on that. And last, the guidance — I can keep this simple.

Andrea Cangioli

executive
#23

Our goal is to surpass 2024 on both revenues and EBIT, and that's what we're planning for. On the revenue target, we remain on schedule. Where the EBIT target is concerned, we're only slightly behind, though we are recovering and feel confident about reaching the 23 million figure in EBIT during the fourth quarter of 2025. Thank you for your patience, and I believe we're ready for your questions.

Moderator

operator
#24

Andrea, Giovanni Salvetti from Berenberg has the first question on our list. Go ahead, Giovanni, please.

Giovanni Salvetti

executive
#25

Hi, everyone. Is my audio coming through clearly?

Andrea Cangioli

executive
#26

Yes. Hello, Giovanni. Yes, we can. Ciao, ciao.

Giovanni Salvetti

executive
#27

I had two, but let's just say the final remarks brought a few extra questions, so maybe I'll get in the queue and ask more afterward. These two concern the medical division. The first is about Asclepion, which according to the press release appears to be performing much better in Q3. As far as I recall, Asclepion was also mainly involved in hair removal, the area that was struggling the most, so I was wondering what exactly has changed, also because if I remember right, in the first half the cost of personnel was rising in relation to Asclepion as well. The second one is about Quanta. If I look at your press release, you're saying that optical fibers now account for more than 50% of medical services. If we assume, let's just say, a figure around 35, that is, let's just say, more than 50%, if we had to double this capacity, do you already see demand to fill it, or how much should we think before the excess capacity gets filled? Maybe the last one is on the Lasit, let's just say, part of the business, that, again, based on what you're saying, we're talking about margins, based on what the press release said, strongly above last year, I was wondering what kind of margins Lasit is now running at.

Giovanni Salvetti

executive
#28

Thank you.

Andrea Cangioli

executive
#29

All right, beginning with Asclepion — yes, there was a rebound. And that rebound was also connected to stronger hair removal results during the third quarter. That's a solid figure when you look at the hair removal business. Yes, staff costs at Asclepion carry a fairly heavy impact. Those costs climbed sharply across the first half. Because third-quarter revenue came in exceptionally strong, the gap in staff-cost impact between Asclepion and the remainder of the group has now narrowed. Above all, what truly drove the turnaround this quarter for Asclepion's business was revenue growth, coming from aesthetics as well as from its surgical line, which is doing very, very well. On Quanta System and fibers, as things stand we don't believe our production capacity is constraining fiber deliveries, or materially constraining them, but we do believe that, with the pace of new installations and the market's uptake of our optical fibers, capacity had to be expanded so we won't run into a sales limitation caused by capacity down the road. Volumes are being raised step by step, and we're making this rather sizeable investment to boost production capacity — though there is no pressing need on our side.

Andrea Cangioli

executive
#30

This is a strategic programming approach that should let us keep growing this revenue stream smoothly over time. Then, your third question concerned Lasit. Sales volume at Lasit has actually not been improving across the nine months, largely because of sluggish behavior in the Italian market, whereas we're performing very well, particularly in Europe, where the subsidiaries Lasit established locally are now really starting to be accretive to the business. I recall we have subsidiaries in Poland, the oldest one; in Spain; Germany; UK; and France, the last one. There are five subsidiaries, and quarter after quarter, they're becoming accretive to revenues and especially to profitability. On profitability, we had an EBIT margin just shy of 8% after the first nine months of 2024. After the first nine months of 2025, we are exceeding 11% as EBIT margin. Those are unaudited financial results referring to the consolidated financial results of Lasit and its subsidiaries.

Giovanni Salvetti

executive
#31

Thanks. Thanks a lot. Let me get into the queue here, and after that I might have a few questions. Okay.

Moderator

operator
#32

Andrea Bonfà from Banca Akros has the second question. Please proceed, Andrea.

Andrea Bonfà

analyst
#33

Hello there, and good afternoon, everyone. I hope my voice is coming through clearly. I’ll jump right in and follow up on what you said last about M&A and possible M&A. From what I gathered, a transformational deal could be on the table, though it isn’t likely at this point, while certain bolt-on acquisitions are clearly more feasible. Could you share which sector, which niches, and which technology you’re targeting?

Enrico Romagnoli

executive
#34

Nope. Alright.

Andrea Bonfà

analyst
#35

Or where, in the end, geographically speaking?

Andrea Cangioli

executive
#36

I apologize. That's everything I'm able to share.

Andrea Bonfà

analyst
#37

Alright. Alright.

Andrea Cangioli

executive
#38

My response stays the same. As I mentioned, we have multiple items in our pipeline tied to both medical and industrial, and those are located in Europe as well as elsewhere around the globe. Since I'm replying this way, there's no further detail I can provide. That wouldn't be fair. All I can say is that we're looking at a number of situations.

Andrea Bonfà

analyst
#39

Alright. Thanks, Andrea. If I can, on the industrial side, with what you just brought up recently, does the US remain a potentially significant market, or given the duties now and your smaller size, let's say, is it less so? The third question concerns the US duties. How is the trading climate in the US at present under this new duties situation, if you can say? And also in relative terms, since perhaps other countries are now less competitive than Europe.

Andrea Cangioli

executive
#40

The US market for our industrial cutting systems remains very interesting and is still the primary market—and the international market—for our systems. As Enrico said explicitly and as I confirm, we have suffered from the image that was projected during the negotiation with the YAC for the sale of the company, and we spent quite a lot of time convincing our US customers that we were not becoming Chinese. Also, after the deal that was going to have Cutlite Penta fall under Chinese control was canceled, we still have a hard time in discussions with our US partners—and I mean partners because we have distribution partners—making them fully comfortable that we will be able to provide them on the midterm a sound, price-attractive and technologically attractive Italian-made product. By the way, they're visiting us on Wednesday in order to clarify this situation again, because based on this, we have had some sort of fluctuation in order bookings from the United States, notwithstanding our efforts, which include a massive deployment of technical service people in order to serve with top quality our systems installed in the United States, and also a strong investment in terms of fairs.

Andrea Cangioli

executive
#41

We took part in FABTECH, which ranks among the priciest trade shows you can attend in the industrial systems market. Having said all that, I'd tell you that yes, the US market remains an opportunity. It's still a significant opportunity, and duties aren't the problem. Duties do affect us in the industrial sector, but duties are not what has caused a slowdown in sales to the United States in the industrial business today. As for the duty issue on the medical system, sure, duties exist, and their impact is quite significant, but over the last months we've seen growing interest from our US customers in our products. That tells us that although every single one of our customers in the United States will attempt to negotiate a deal so that we take on the quoted undue extra cost driven by duties, they keep seeking us out because we can give them the innovative product content that lets them earn margin despite the extra cost. Essentially, right now, at least for the first 10 months of the year, we're very pleased with our results in terms of revenues and also with what we've achieved in terms of order bookings.

Andrea Cangioli

executive
#42

After that, naturally, we’ll need to watch how the peak season in the US market—that’s December—plays out as we roll out for our distributors, so they can make a final call on the full impact of duties on our US business. So far, we’re seeing an overall positive response from the US market to the duty situation.

Andrea Bonfà

analyst
#43

Thanks, Andrea. You're

Andrea Cangioli

executive
#44

Thanks for joining us.

Moderator

operator
#45

Carlo Maritano from Intermonte has the next question. Please go ahead, Carlo.

Carlo Maritano

analyst
#46

Is this coming through okay?

Andrea Cangioli

executive
#47

Yes, that's absolutely fine, Carlo. Hello.

Carlo Maritano

analyst
#48

Okay, hello everybody. I’ve got just a couple of questions. First, regarding the European performance in the industrial cutting business during the third quarter: I notice there’s a decline versus last year. I’m wondering whether that ties to the €9 million of revenue that moved out of the third quarter and into the fourth quarter. Second, also on the industrial business, this time Italy: the government recently changed again the incentives tied to Transizione 5.0, and I’m wondering whether you anticipate any kind of impact on your clients from that change, or whether the order book stays healthy and you don’t expect any kind of disruption. Thank you.

Andrea Cangioli

executive
#49

Thanks for those two questions. On the first one, regarding the drop in European industrial revenue, you can see it in Q3, and it's something that is, let's say, localized. It isn't connected to the cut-off, which is primarily an Italian matter. It's primarily an Italian matter since it's linked to the delivery methods we use in Italy, and what we could say is that it has been driven by softer activity in Europe and by the subsidiaries' slower activity. We should be able to get past this situation over the remainder of the year. As for the Italian funding situation, I didn't want to go into that level of detail, but of course, we are looking at the effects of the cut-off that the Italian government placed on Industry 5.0, and this might have some impact. I'm not able to quantify it. It shouldn't be determinant, but it could be material. The good news is that it appears the new law for 2026 could be interesting for investors, and so we might experience a marginal correction. We have an order book, but some of those orders may not turn into sales because of the change in approach by the Italian government, as the money for Industry 5.0 is exhausted, but we should be supported, hopefully, without the hesitation that occurred in 2025 also in 2026 for a certain level of investments.

Carlo Maritano

analyst
#50

Thanks.

Moderator

operator
#51

Andrea, there’s another question coming from Emanuele De Figueredo. I’ll read it on his behalf because of a connection issue. His question is: what made medical perform so strongly in Italy compared with other markets?

Andrea Cangioli

executive
#52

Naturally, that's a highlight. It's a highlight since we achieved tremendous results, and since I think we did remarkably well with the distribution of DEKA, Renaissance in Italy, which is set to reach a record goal, a record figure. We also made some sales in professional beauty that lift its volume steadily, and demand remains extremely, extremely strong. What's the reason? I think the team we now have in Italy gives our end customers a level of service without equal. We have, I believe, 8 product managers who are constantly on the road across Italy when they're not based in a region, since naturally the key regions have product specialists who are always supporting our customers. As we said earlier, we don't confine our activity to supplying the laser box to our customers; we also provide ongoing training. We provide very, very — I wouldn't call it cheap, but affordable service so they can get the greatest benefit from the lasers we've sold them. Because they're happy, because they earn money with our lasers, they return and purchase. This 2025 will be a record year for Italy, and that's the only explanation I can offer on this point.

Moderator

operator
#53

Thanks, Andrea. We’ve got another question, this one from Andrea Bonfà at Bonfà Akros. Please go ahead, Andrea. Hello.

Andrea Bonfà

analyst
#54

Thanks again for taking my question, and sorry about that. Andrea, just quickly: the figures you gave near the start of the call — the like-for-like number, 7.9% excluding the Japanese subsidiary and over 10% excluding Cynosure — do those apply only to the medical division, or to the group as a whole?

Andrea Cangioli

executive
#55

The medical division.

Andrea Bonfà

analyst
#56

Appreciate it.

Andrea Cangioli

executive
#57

The point I was making is that, in a stable environment, we're reaching the 10% revenue growth target after nine months. That's the message I intended to convey with those remarks.

Andrea Bonfà

analyst
#58

Thanks once more.

Moderator

operator
#59

At this point, we don't have any further questions registered. I'd like to —

Andrea Cangioli

executive
#60

Giovanni Salvetti mentioned that he had additional questions he was hoping to raise. Perhaps we’ve already addressed them, though I’m not certain. He indicated that he wanted to.

Giovanni Salvetti

executive
#61

to — Giovanni,

Moderator

operator
#62

Please continue.

Giovanni Salvetti

executive
#63

Some of that has been addressed already, yeah. Let me frame it like this: I don't want to push for too much detail on M&A, right, also since there's only so much you can share, but the question was more about whether these companies are more, say, technology-focused businesses that bring tech on board or businesses that already have real sales, right? It comes down to whether you're putting money into technology or into market share. I'm not sure you're able to answer that, so...

Andrea Cangioli

executive
#64

Our basket holds everything. Whatever flavor you want, it's in our potential basket — you've got both kinds. Whether we'll close, and what exactly, I can't say. Once more, please don't set expectations too wide here. These are small transactions we're discussing, yet we have solutions on both the technology side and the sales side, along with sales opportunities.

Giovanni Salvetti

executive
#65

Alright. Thanks. Thanks a lot.

Andrea Cangioli

executive
#66

You're welcome. After that,

Moderator

operator
#67

Right now, there aren't any more questions. Once more, I'd like to check whether any investors who are still on the line have anything further to ask. There are no additional questions. With that, ladies and gentlemen, we're bringing this conference to a close. Should you have any inquiries going forward, please feel free to reach out to Enrico Romagnoli, who will be glad to help you. Thank you for joining this conference and for taking part, and we look forward to having all of you with us again next time. Goodbye, everyone.

Andrea Cangioli

executive
#68

So long, everyone. Thanks a lot, Bianca. Appreciate it, Enrico. Thanks.

Operator

operator
#69

You. Thank you. Bye-bye.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete EL.En. S.p.A. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

For developers and AI pipelines

Programmatic access to EL.En. S.p.A. earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in EL.En. S.p.A. or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.